Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01468012 · ClinicalTrials.gov registry record · Phase 2
Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT01468012 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 23 participants.
The verdict
NCT01468012, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The proposed study will look at cocaine dependent individuals and will consist of three consecutive phases: 1) the 2-week outpatient lead-in phase during which behavioral therapy will be administered; 2) the 15-21 day inpatient phase (during which participants will start study medication of levodopa,carbidopa and entacapone (LCE) and will undergo brain imaging and 3) the 24 weeks outpatient treatment trial. The purpose is to see if treatment with LCE may reverse baseline brain deficits and if this change is associated with clinical improvement. Hypothesis is that treatment with LCE, compared to placebo, increases abstinence from cocaine over a 12-week trial in combination with behavioral treatment with voucher incentives.
Interventions
- DRUG Placebo
- DRUG levodopa carbidopa and entacapone (LCE)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01468012
The ClinicalTrials.gov registry entry for NCT01468012 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01468012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01468012 about?
NCT01468012 is a clinical study titled "Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence". The proposed study will look at cocaine dependent individuals and will consist of three consecutive phases: 1) the 2-week outpatient lead-in phase during which behavioral therapy will be administered; 2) the 15-21 day inpatient phase (during which participants will start study medication of levodopa...
What is the current status of trial NCT01468012?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2014-07. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01468012?
The interventions under investigation include: Placebo (DRUG), levodopa carbidopa and entacapone (LCE) (DRUG).
Who is sponsoring clinical trial NCT01468012?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.